Clinical Decision Support Archives - Medical Design Sourcing

Devices, disease, and digital: Holy Grail of healthcare AI

[Image courtesy of GE HealthCare]

In episode 3 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown and Pharma and Biotech Editor Brian Buntz sit down with GE HealthCare Chief Digital Officer and GM of Oncology Ben Newton and Haley Schwartz of Catalyze Healthcare to discuss the impacts of AI to screen, diagnose, prognose, and treat cure disease while addressing real-world implementation issues from regulation and liability to clinician trust and adoption. They review the AI challenge of organizing disarrayed informational islands such as technology, clinical protocols, and digital solutions into cohesive, well-developed systems and offer insight into the medtech industry’s progress in this area.

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

The AI Holy Grail for …

Devices, disease, and digital: Holy Grail of healthcare AI

[Image courtesy of GE HealthCare]

In episode 3 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown and Pharma and Biotech Editor Brian Buntz sit down with GE HealthCare Chief Digital Officer and GM of Oncology Ben Newton and Haley Schwartz of Catalyze Healthcare to discuss the impacts of AI to screen, diagnose, prognose, and treat cure disease while addressing real-world implementation issues from regulation and liability to clinician trust and adoption.

They review the AI challenge of organizing disarrayed informational islands such as technology, clinical protocols, and digital solutions into cohesive, well-developed systems and offer insight into the medtech industry’s progress in this area.

The AI Holy Grail for decision support

Ben Newton

AI technologies emerged quickly over the last several years in medical imaging and oncology…

ConcertAI acquisition will boost CancerLinQ data capabilities with AI focus

The AI oncology startup ConcertAI recently acquired CancerLinQ, one of the largest oncology real-world data and quality of care technology service entities. Originally developed by the American Society of Clinical Oncology (ASCO) in 2013, CancerLinQ aims to use real-world data and technology to improve cancer care and advance evidence-based research.

CancerLinQ has developed one of the “deepest, broadest, most generalizable, least biased single standalone data sources that exists in oncology,” according to Jeff Elton, CEO of ConcertAI. This real-world data asset encompasses clinical data across more than 7 million patients, 100 care sites and more than 10 EMR systems.

Boosting CancerLinQ’s scope and capabilities

The acquisition will bring considerably more resources to CancerLinQ, which had a dedicated staff of between 50 and 60 people in comparison to ConcertAI, which has more than 1,100 employees. Under terms of the deal, ASCO will mainta…